Fixed drug combinations as a way of complex antihypertensive therapy optimization: focus on the combination of amlodipine, indapamide, perindopril
https://doi.org/10.18705/1607-419X-2022-28-1-17-26
Abstract
This article is an analysis of current data on arterial hypertension (HTN) as a leading risk factor for premature death. We discuss the reasons of the failure to achieve target levels of blood pressure, and the available approaches to HTN pharmacological treatment by the main classes of antihypertensive drugs in accordance with current clinical guidelines. We show the advantages of fixed combinations (FC) of antihypertensive drugs and the ways to optimize antihypertensive treatment by administration of a triple FC, containing amlodipine, indapamide and perindopril.
About the Authors
S. V. Povetkin
Kursk State Medical University
Russian Federation
Russian Federation
Sergey V. Povetkin, MD, PhD, DSc, Professor, Head, Department of Clinical Pharmacology
Kursk
A. A. Kornilov
Kursk State Medical University
Russian Federation
Russian Federation
Arsen A. Kornilov, MD, PhD, Associate Professor, Department of Clinical Pharmacology
3 K. Marksa str., Kursk, 305041
References
1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al. Global burden of hypertension and systolic blood pressure of at Least 110 to 115 mm Hg, 1990–2015. J Am Med Assoc. 2017;317(2):165–182.
2. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. J Am Med Assoc. 2013;310(9):959–968.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223.
4. Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jorgensen T et al. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension. 2012;60(5):1117–1123.
5. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens. 2007;20(3):338–341.
6. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707–716.
7. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Rossijskij Kardiologicheskij Zhurnal = Russian Journal of Cardiology. 2018;23(12):143–228. doi:10.15829/1560-4071-2018-12-143-228. In Russian.
8. Privalova EV, Lishuta AS. Antihypertensive efficacy of a threecomponent fixed combination of perindopril, indapamide and amlodipine: clinical efficacy in outpatient practice (discussion of the results of the PETRA study). Kardiologiia. 2018;58(11):63–71. In Russian.
9. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. NCD Risk Factor Collaboration. Lancet. 2021;398(10304):957– 980. doi:10.1016/S0140-6736(21)01330-1
10. Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17): 2143–2152.
11. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285–2295.
12. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment for prevention of heart failure and new-onset heart failure — meta-analyses of randomized trials. J Hypertens. 2016;34(3):373–384.
13. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J et al. Blood pressure-lowering treatment trialists’ collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162(3):184–191.
14. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levelsoverview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2296–2304.
15. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network metaanalysis. JAMA Cardiol. 2017;2(7):775–781. doi:10.1001/jamacardio.2017.1421
16. Kobalava ZD, Konradi AO, Nedogoda SV, Arutyunov GP, Baranova EI, Barbarash OL et al. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;(12):131–142. doi:10.15829/1560-4071-2018-12-131-142. In Russian.
17. Kobalava ZD, KonradiAO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020.Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.
18. Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(1):28–36.
19. Ettehad D, Emdin CA, Kiran A, Anderson SG, CallenderT, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet. 2016;387(10022):957–967.
20. Rutten FH, Zuithoff NP, Halk F, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–887.
21. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Headto-head comparisons of various classes of antihypertensive drugs— overview and meta-analyses. J Hypertens. 2015;33(7):1321–1341.
22. Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T et al. Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP Study. Circulation. 2020;142(19):1810–1820.
23. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61. doi:10.1161/HYPERTENSIONAHA.107.100727
24. Dusing R, Waeber B, Destro M, Maia CS, Brunel P. Triplecombination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens. 2017;31(8):501–510. doi:10.1038/jhh.2017.5
25. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116(5A):30S–38S.
26. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet. 2005;366(9489):895–906.
27. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869–878.
28. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584–1590.
29. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
30. Parati G, Lombardi C, Pengo M, Bilo G, Ochoa JE. Current challenges for hypertension management: From better hypertension diagnosis to improved patients’ adherence and blood pressure control. Int J Cardiol. 2021;331:262–269. doi:10.1016/j.ijcard.2021.01.070
31. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339
32. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584–1590. doi:10.1097/HJH.0b013e328339f9fa
33. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407. doi:10.1161/HYPERTENSIONAHA.109.139816
34. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–774. doi:10.1097/HJH.0b013e32835e228
35. Konradi AO. Triple fixed combination of antihypertensive drugs is a green light in the context of the new European guidelines 2018. Arterial’naya Gipertenziya = Arterial Hypertension. 2018;24(6):716–722. doi:10.18705/1607-419X‑2018-24-6-716-722. In Russian.
36. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC Guidelines for themanagement of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219.
37. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B; Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;343: d4891. doi:10.1136/bmj.d4891
38. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371(9631):2219–2221.
39. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
40. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590):829–840. doi:10.1016/S0140-6736(07)61303-8
41. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428.
42. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A et al. The Felodipine EVEnt Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157–2172.
43. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SystEur) Trial Investigators. Lancet. 1997;350(9080):757–764.
44. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160(2):211–220.
45. Poteshkina NG, Selivanova GB, Zhalsaraev TZh. Angiotensin II receptor antagonists in the treatment of arterial hypertension: prospects for clinical application. Arterial’naya Gipertenziya = Arterial Hypertension. 2013;2(19):117–124. In Russian.
46. Buvaltsev VI. Endothelial dysfunction as a new concept of prevention and treatment of cardiovascular disease. Mezhdunarodniy Meditsinskiy Zhurnal = International Medical Journal. 2001;3(7):202–208. In Russian.
47. Kisljak OA. Angiotensin receptor blockers: current approaches to the treatment of hypertension. Russkiy Meditsinskiy Zhurnal = Russian Medical Journal.2004;12(15):935–941. In Russian.
48. Preobrazhensky DV, Sidorenko BA, Ivanova NA, Stetsenko TM, Shcheglova IYu. AT1-angiotensin receptor blockers: features of clinical pharmacology and experience of use in the treatment of hypertension. Arterial’naya Gipertenziya = Arterial Hypertension. 2003;9(4):117–123. doi:10.18705/1607-419X‑2003-9-4-117-123. In Russian.
49. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.
50. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–1041.
51. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–2226.
52. ALLHAT. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
53. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63(2):259–264.
54. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. J Hypertens. 2008;26(10):1919–1927.
55. Kobalava ZhD, Troitskaya EA, Tolkacheva VV. Combined therapy of arterial hypertension with triple fixed-dose combination of amlodipine/indapamide/perindopril arginine in real clinical practice: the organization and the main results of the DOKAZATEL’STVO (Proof) Study. Kardiologiia. 2018;58(9):21–30. doi:10.18087/cardio.2018.9.10170. In Russian.
56. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory bloodpressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407–2415.
57. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111(14):1777–1783.
58. Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz J et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378(16):1509–1520.
59. Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens. 2014;32(12):2332– 2340; discussion 2340.
60. Fagard RH, Celis H, Thijs L, Staessen J, Clement DL, De Buyzere M et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61.
61. Parati G, Ochoa JE, Bilo G, Agarwal R, Covic A, Dekker FW et al. European Renal and Cardiovascular Medicine Working Group of the European Renal Association-European Dialysis and Transplant Association. Hypertension in chronic kidney disease part 2: role of ambulatory and home blood pressure monitoring for assessing alterations in blood pressure variability and blood pressure profiles. Hypertension. 2016;67(6):1102–1110.
62. Yano Y, Kario K. Nocturnal blood pressure and cardiovascular disease: a review of recent advances. Hypertens Res. 2012;35(7):695–701. doi:10.1038/hr.2012.26
63. Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. 2013;61(2):278–283. doi:10.1161/HYPERTENSIONAHA.111.00217
64. Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. J Am Med Assoc. 2019;322(5):409–420. doi:10.1001/jama.2019.9811
65. Wang C, Li Y, Zhang J, Ye Z, Zhang Q, Ma X et al. Prognostic effect of isolated nocturnal hypertension in Chinese patients with nondialysis chronic kidney disease. J Am Heart Assoc. 2016;5(10):e004198. doi:10.1161/JAHA.116.004198
66. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood pressure variability. Nat Rev Cardiol. 2013;10(3):143–155. doi:10.1038/nrcardio.2013.1
67. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G et al. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359–1366.
68. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116(6):1034–1045.
69. Salles GF, Reboldi G, Fagard RH, Cardoso CRL, Pierdomenico SD, Verdecchia P et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis. Hypertension. 2016;67(4):693–700.
70. Mancia G. Short- and long-term blood pressure variability: present and future. Hypertension. 2012;60(2):512–517.
71. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10):1401–1406.
72. Parati G, Schillaci G. What are the real determinants of the ambulatory arterial stiffness index? J Hypertens. 2012;30(3): 472–476.
73. Karpov YA, Gorbunov VM, Logunova NA on behalf of the TRICOLOR research team. Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR. Rossijskij Kardiologicheskij Zhurnal = Russian Journal of Cardiology. 2020;25(10): 4130. doi:10.15829/1560-4071-2020-4130. In Russian.
74. Gorbunov VM, KarpovYuA, Platonova EV, Koshelyaevskaya YaN on behalf of the group of researchers of the TRICOLOR program. Daily monitoring and clinical measurement of blood pressure in a comprehensive assessment of the effectiveness of 12-week therapy with a triple fixed combination of amlodipine/indapamide/perindopril in patients with hypertension in real clinical practice. Rossijskij Kardiologicheskij Zhurnal = Russian Journal of Cardiology. 2021;26(5):4498. doi:10.15829/1560-4071-2021-4498. In Russian.
75. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014;34(10):701–708. doi:10.1007/s40261-014-0223-0
76. Tóth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST Study (PerindoprilIndapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137–145. doi:10.1007/s40256-014-0067-2
77. Abraham G, Dezsi CA. The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: the results of the PETRA Study. Adv Ther. 2017;34 (7):1753–1763. doi:10.1007/s12325-017-0572-1
78. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J. 2003;326(7404):1427. doi:10.1136/bmj.326.7404.1427
79. Bennett A, Chow CK, Chou M, Dehbi HM, Webster R, Salam A et al. Efficacy and safety of quarter-dose blood pressurelowering agents: a systematic review and meta-analysis of randomized controlled trials. Hypertension. 2017;70(1):85–93. doi:10.1161/HYPERTENSIONAHA.117.09202
Review
For citations:
Povetkin S.V., Kornilov A.A. Fixed drug combinations as a way of complex antihypertensive therapy optimization: focus on the combination of amlodipine, indapamide, perindopril. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2022;28(1):17-26. (In Russ.) https://doi.org/10.18705/1607-419X-2022-28-1-17-26
Views:
1110
Email this article 